Skip to main content
. 2021 Feb 18;11(2):39. doi: 10.1038/s41408-021-00429-z

Fig. 4. Combination of ibrutinib and venetoclax effectively eliminates both resting and dividing CLL subpopulations in ibrutinib-sensitive cases.

Fig. 4

CFSE-labeled CLL cells were cultured with BMF+CpG/IL-15 in the presence of DMSO, 400 nM of ibr, 200 nM of venetoclax (ven) or both. All analyses shown were conducted at day 7 of the co-culture by flow cytometry. Live cell numbers (bar graphs) and CFSE profiles of four ibrutinib naïve/sensitive cases are shown. Live cell numbers were normalize to the DMSO control (100%). Percentage of cells distributed in the dividing phases of the CFSE profiles is automatically calculated by the FlowJo software. Y axis scale-auto displays events on the same scale for all treatment conditions, and Y axis scale-Modal displays events on an extended scale to show low peaks under the conditions of ventoclax or combination treatment.